- Home
- STTK vs RGS Comparison
STTK vs RGS Comparison
Compare STTK & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- RGS
- Stock Information
- Founded
- STTK 2016
- RGS 1922
- Country
- STTK United States
- RGS United States
- Employees
- STTK N/A
- RGS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- RGS Other Consumer Services
- Sector
- STTK Health Care
- RGS Consumer Discretionary
- Exchange
- STTK Nasdaq
- RGS Nasdaq
- Market Cap
- STTK 83.8M
- RGS 70.8M
- IPO Year
- STTK 2020
- RGS 1991
- Fundamental
- Price
- STTK $2.14
- RGS $28.45
- Analyst Decision
- STTK Hold
- RGS
- Analyst Count
- STTK 6
- RGS 0
- Target Price
- STTK $2.67
- RGS N/A
- AVG Volume (30 Days)
- STTK 1.5M
- RGS 23.9K
- Earning Date
- STTK 11-13-2025
- RGS 11-05-2025
- Dividend Yield
- STTK N/A
- RGS N/A
- EPS Growth
- STTK N/A
- RGS 20.23
- EPS
- STTK N/A
- RGS 46.10
- Revenue
- STTK $2,997,000.00
- RGS $210,134,000.00
- Revenue This Year
- STTK N/A
- RGS N/A
- Revenue Next Year
- STTK N/A
- RGS N/A
- P/E Ratio
- STTK N/A
- RGS $0.68
- Revenue Growth
- STTK N/A
- RGS 3.52
- 52 Week Low
- STTK $0.69
- RGS $15.00
- 52 Week High
- STTK $3.95
- RGS $30.29
- Technical
- Relative Strength Index (RSI)
- STTK 58.93
- RGS 70.52
- Support Level
- STTK N/A
- RGS $22.00
- Resistance Level
- STTK $2.01
- RGS $30.29
- Average True Range (ATR)
- STTK 0.21
- RGS 1.54
- MACD
- STTK 0.01
- RGS 0.67
- Stochastic Oscillator
- STTK 99.53
- RGS 80.89
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About RGS Regis Corporation
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.